trial · primary record
Combined metabolic activators
Gout Disease
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 336 |
| Primary completion | 2027-02 |
| Primary endpoint | To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo. |
| Registry ID | NCT07889284 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:44.667Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07889284
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.